Catherine Madigan
Chief Tech/Sci/R&D Officer bei SYNDAX PHARMACEUTICALS, INC.
Vermögen: 859 918 $ am 31.03.2024
Profil
Catherine Madigan is currently the Chief Medical Officer at Syndax Pharmaceuticals, Inc. She previously worked as the Senior Medical Director at Alnylam Pharmaceuticals, Inc. and as the Vice President & Head-Clinical Development at Syros Pharmaceuticals, Inc. Dr. Madigan completed her undergraduate degree at Dartmouth College and obtained her doctorate degree from Keck School of Medicine of USC.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 08.03.2024 | 36 131 ( 0,04% ) | 859 918 $ | 31.03.2024 |
Aktive Positionen von Catherine Madigan
| Unternehmen | Position | Beginn |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.03.2022 |
Ehemalige bekannte Positionen von Catherine Madigan
| Unternehmen | Position | Ende |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| SYROS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Catherine Madigan
| Dartmouth College | Undergraduate Degree |
| Keck School of Medicine of USC | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| SYROS PHARMACEUTICALS, INC. | Health Technology |
